164 related articles for article (PubMed ID: 35213857)
1. Construction of a lung adenocarcinoma prognostic model based on N6-methyl-adenosine-related long noncoding RNA and screening of potential drugs based on this model.
Hou Q; Zhong Y; Liu L; Wu L; Liu J
Anticancer Drugs; 2022 Apr; 33(4):371-383. PubMed ID: 35213857
[TBL] [Abstract][Full Text] [Related]
2. Relationships of N6-Methyladenosine-Related Long Non-Coding RNAs With Tumor Immune Microenvironment and Clinical Prognosis in Lung Adenocarcinoma.
Zhao J; Lin X; Zhuang J; He F
Front Genet; 2021; 12():714697. PubMed ID: 34777460
[No Abstract] [Full Text] [Related]
3. Risk stratification of lung adenocarcinoma using a nomogram combined with ferroptosis-related LncRNAs and subgroup analysis with immune and N6-methyladenosine modification.
Gao C; Kong N; Zhang F; Tang T; Li J; Ding H; Sun Z; Wu L; Xu M
BMC Med Genomics; 2022 Jan; 15(1):15. PubMed ID: 35093068
[TBL] [Abstract][Full Text] [Related]
4. Development and validation of the potential biomarkers based on m6A-related lncRNAs for the predictions of overall survival in the lung adenocarcinoma and differential analysis with cuproptosis.
Gao C; Kong N; Zhang F; Zhou L; Xu M; Wu L
BMC Bioinformatics; 2022 Aug; 23(1):327. PubMed ID: 35941550
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive analysis of m6A modification patterns and m6A-related lncRNAs as potential biomarkers in lung adenocarcinoma.
Wang S; Gu X; Xu D; Liu B; Qin K; Yuan X
Environ Toxicol; 2024 Apr; 39(4):2285-2303. PubMed ID: 38148718
[TBL] [Abstract][Full Text] [Related]
6. Construction of an m6A-related lncRNA model for predicting prognosis and immunotherapy in patients with lung adenocarcinoma.
Shen HY; Zhang J; Xu D; Xu Z; Liang MX; Chen WQ; Tang JH; Xia WJ
Medicine (Baltimore); 2023 Apr; 102(15):e33530. PubMed ID: 37058053
[TBL] [Abstract][Full Text] [Related]
7. A cuproptosis-related lncRNA signature for predicting prognosis and immunotherapy response of lung adenocarcinoma.
Yu S; Tang L; Zhang Q; Li W; Yao S; Cai Y; Cheng H
Hereditas; 2023 Jul; 160(1):31. PubMed ID: 37482612
[TBL] [Abstract][Full Text] [Related]
8. Development and validation of a novel N6-methyladenosine (m6A)-related multi- long non-coding RNA (lncRNA) prognostic signature in pancreatic adenocarcinoma.
Yuan Q; Ren J; Li L; Li S; Xiang K; Shang D
Bioengineered; 2021 Dec; 12(1):2432-2448. PubMed ID: 34233576
[TBL] [Abstract][Full Text] [Related]
9. A ferroptosis-related LncRNAs signature for predicting prognoses and screening potential therapeutic drugs in patients with lung adenocarcinoma: A retrospective study.
Dong J; Tao T; Yu J; Shan H; Liu Z; Zheng G; Li Z; Situ W; Zhu X; Li Z
Cancer Rep (Hoboken); 2024 Jan; 7(1):e1925. PubMed ID: 38043920
[TBL] [Abstract][Full Text] [Related]
10. Prognostic model and immunotherapy prediction based on molecular chaperone-related lncRNAs in lung adenocarcinoma.
Xu Y; Tao T; Li S; Tan S; Liu H; Zhu X
Front Genet; 2022; 13():975905. PubMed ID: 36313456
[No Abstract] [Full Text] [Related]
11. Methylation of N6 adenosine-related long noncoding RNA: effects on prognosis and treatment in 'driver-gene-negative' lung adenocarcinoma.
Yang HS; Cai HY; Shan SC; Chen TF; Zou JY; Abudurufu M; Luo HH; Lei YY; Ke ZF; Zhu Y
Mol Oncol; 2023 Feb; 17(2):365-377. PubMed ID: 36221911
[TBL] [Abstract][Full Text] [Related]
12. Immunoprognostic model of lung adenocarcinoma and screening of sensitive drugs.
Liang P; Li J; Chen J; Lu J; Hao Z; Shi J; Chang Q; Zeng Z
Sci Rep; 2022 May; 12(1):7162. PubMed ID: 35504892
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Value of Genomic Instability of m
Li R; Li JP; Liu TT; Huo C; Yao J; Ji XL; Qu YQ
Front Cell Dev Biol; 2022; 10():707405. PubMed ID: 35309906
[No Abstract] [Full Text] [Related]
14. Characteristic of molecular subtypes in lung adenocarcinoma based on m6A RNA methylation modification and immune microenvironment.
Zhou H; Zheng M; Shi M; Wang J; Huang Z; Zhang H; Zhou Y; Shi J
BMC Cancer; 2021 Aug; 21(1):938. PubMed ID: 34416861
[TBL] [Abstract][Full Text] [Related]
15. Identification of Fatty Acid Metabolism-Related lncRNAs as Biomarkers for Clinical Prognosis and Immunotherapy Response in Patients With Lung Adenocarcinoma.
Wang H; Cui J; Yu J; Huang J; Li M
Front Genet; 2022; 13():855940. PubMed ID: 35464865
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive Analysis of N6-Methyladenosine-Related lncRNA Signature for Predicting Prognosis and Immune Cell Infiltration in Patients with Colorectal Cancer.
Zhao Z; Yang YB; Li XY; Li XG; Chu XD; Lin ZB; Zhang YR; Guo YG; Ding H; Pan YL; Wang L; Pan JH
Dis Markers; 2021; 2021():8686307. PubMed ID: 34745388
[TBL] [Abstract][Full Text] [Related]
17. Identification and validation of tryptophan metabolism-related lncRNAs in lung adenocarcinoma prognosis and immune response.
Gao M; Wang M; Chen Y; Wu J; Zhou S; He W; Shu Y; Wang X
J Cancer Res Clin Oncol; 2024 Apr; 150(4):171. PubMed ID: 38558328
[TBL] [Abstract][Full Text] [Related]
18. Construction of a Prognostic Immune-Related LncRNA Risk Model for Lung Adenocarcinoma.
Li Y; Shen R; Wang A; Zhao J; Zhou J; Zhang W; Zhang R; Zhu J; Liu Z; Huang JA
Front Cell Dev Biol; 2021; 9():648806. PubMed ID: 33869203
[TBL] [Abstract][Full Text] [Related]
19. A disulfidptosis-related lncRNA signature for predicting prognosis and evaluating the tumor immune microenvironment of lung adenocarcinoma.
Song Z; Cao X; Wang X; Li Y; Zhang W; Wang Y; Chen L
Sci Rep; 2024 Feb; 14(1):4621. PubMed ID: 38409243
[TBL] [Abstract][Full Text] [Related]
20. N-6 methylation-related lncRNA is potential signature in lung adenocarcinoma and influences tumor microenvironment.
Zheng J; Zhao Z; Wan J; Guo M; Wang Y; Yang Z; Li Z; Ming L; Qin Z
J Clin Lab Anal; 2021 Nov; 35(11):e23951. PubMed ID: 34558724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]